Calling it a play on the “golden silver economy”, analyst Paul Yong sees the stock as currently trading at an “undemanding valuation” at 22.0 times FY2022 price-to-earnings (P/E).
DBS Group Research has initiated “buy” on Econ Healthcare (Asia) with a target price of 40 cents.
The target price represents a 33% upside to the group’s last-closed price of 30 cents on Sept 10.
